KR20190024572A - TNFα 관련 질환을 치료하기 위한 피하 투여 요법 - Google Patents

TNFα 관련 질환을 치료하기 위한 피하 투여 요법 Download PDF

Info

Publication number
KR20190024572A
KR20190024572A KR1020180017449A KR20180017449A KR20190024572A KR 20190024572 A KR20190024572 A KR 20190024572A KR 1020180017449 A KR1020180017449 A KR 1020180017449A KR 20180017449 A KR20180017449 A KR 20180017449A KR 20190024572 A KR20190024572 A KR 20190024572A
Authority
KR
South Korea
Prior art keywords
antibody
antigen
binding fragment
composition
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020180017449A
Other languages
English (en)
Korean (ko)
Inventor
김선정
서지혜
안현철
이성영
Original Assignee
(주)셀트리온
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)셀트리온 filed Critical (주)셀트리온
Priority to EA202090544A priority Critical patent/EA202090544A1/ru
Priority to PCT/KR2018/009998 priority patent/WO2019045452A1/ko
Priority to EP18852415.1A priority patent/EP3677596A4/en
Priority to KR1020180102233A priority patent/KR102921525B1/ko
Priority to MX2020002278A priority patent/MX2020002278A/es
Priority to US16/643,377 priority patent/US20210371510A1/en
Priority to PE2020000292A priority patent/PE20200889A1/es
Priority to JOP/2020/0046A priority patent/JOP20200046A1/ar
Priority to GEAP201815302A priority patent/GEP20237521B/en
Priority to JP2020512018A priority patent/JP7838891B2/ja
Priority to SG11202001739YA priority patent/SG11202001739YA/en
Priority to GEAP202315302A priority patent/GEAP202315302A/en
Priority to CA3074168A priority patent/CA3074168C/en
Priority to CR20200095A priority patent/CR20200095A/es
Priority to CU2020000015A priority patent/CU20200015A7/es
Priority to CN201880055961.9A priority patent/CN111094342A/zh
Priority to MA050046A priority patent/MA50046A/fr
Priority to UAA202001947A priority patent/UA130480C2/uk
Priority to NZ760588A priority patent/NZ760588B2/en
Priority to AU2018326037A priority patent/AU2018326037B2/en
Priority to BR112020003951-9A priority patent/BR112020003951A2/pt
Priority to TW107130340A priority patent/TWI887196B/zh
Priority to TW114103576A priority patent/TWI935652B/zh
Publication of KR20190024572A publication Critical patent/KR20190024572A/ko
Priority to PH12020550066A priority patent/PH12020550066A1/en
Priority to CONC2020/0002117A priority patent/CO2020002117A2/es
Priority to CL2020000479A priority patent/CL2020000479A1/es
Priority to ECSENADI202014569A priority patent/ECSP20014569A/es
Priority to IL272977A priority patent/IL272977A/en
Priority to DO2020000049A priority patent/DOP2020000049A/es
Priority to ZA2020/01927A priority patent/ZA202001927B/en
Priority to JP2023196788A priority patent/JP2024023347A/ja
Priority to US18/774,066 priority patent/US20250002573A1/en
Priority to AU2024216469A priority patent/AU2024216469A1/en
Priority to KR1020240131000A priority patent/KR20240148776A/ko
Priority to ARP250100301A priority patent/AR135171A2/es
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
KR1020180017449A 2017-08-30 2018-02-13 TNFα 관련 질환을 치료하기 위한 피하 투여 요법 Pending KR20190024572A (ko)

Priority Applications (35)

Application Number Priority Date Filing Date Title
UAA202001947A UA130480C2 (uk) 2017-08-30 2018-08-29 СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'ЯЗАНОГО З TNF-<font face="Symbol">a</font>
NZ760588A NZ760588B2 (en) 2018-08-29 Methods for Treating TNFa-Related Diseases
EP18852415.1A EP3677596A4 (en) 2017-08-30 2018-08-29 METHOD OF TREATING A TNF-RELATED ILLNESS
KR1020180102233A KR102921525B1 (ko) 2017-08-30 2018-08-29 TNFα 관련 질환을 치료하는 방법
MX2020002278A MX2020002278A (es) 2017-08-30 2018-08-29 Metodos para el tratamiento de enfermedades relacionadas con tnfa.
BR112020003951-9A BR112020003951A2 (pt) 2017-08-30 2018-08-29 métodos para tratar doenças relacionadas a tnf
PE2020000292A PE20200889A1 (es) 2017-08-30 2018-08-29 METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa)
JOP/2020/0046A JOP20200046A1 (ar) 2017-08-30 2018-08-29 طرق لعلاج أمراض مرتبطة بـtnf?
GEAP201815302A GEP20237521B (en) 2017-08-30 2018-08-29 METHOD FOR TREATING TNFα-RELATED DISEASE
JP2020512018A JP7838891B2 (ja) 2017-08-30 2018-08-29 ＴＮＦα関連疾患の治療方法
SG11202001739YA SG11202001739YA (en) 2017-08-30 2018-08-29 METHOD FOR TREATING TNFα-RELATED DISEASE
GEAP202315302A GEAP202315302A (en) 2017-08-30 2018-08-29 METHOD FOR TREATING TNFα-RELATED DISEASE
CA3074168A CA3074168C (en) 2017-08-30 2018-08-29 Methods for treating tnf.alpha.-related diseases
CR20200095A CR20200095A (es) 2017-08-30 2018-08-29 MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
CU2020000015A CU20200015A7 (es) 2017-08-30 2018-08-29 Composición farmacéutica y kit que comprenden anticuerpos anti-tnf alpha
CN201880055961.9A CN111094342A (zh) 2017-08-30 2018-08-29 用于治疗TNFα相关疾病的方法
MA050046A MA50046A (fr) 2017-08-30 2018-08-29 Méthode de traitement d'une maladie liée au tnf
EA202090544A EA202090544A1 (ru) 2017-08-30 2018-08-29 Способ лечения заболевания, связанного с tnf-
AU2018326037A AU2018326037B2 (en) 2017-08-30 2018-08-29 Method for treating TNFα-related disease
PCT/KR2018/009998 WO2019045452A1 (ko) 2017-08-30 2018-08-29 TNFα 관련 질환을 치료하는 방법
US16/643,377 US20210371510A1 (en) 2017-08-30 2018-08-29 Methods for Treating TNFa-Related Diseases
TW114103576A TWI935652B (zh) 2017-08-30 2018-08-30 用於治療ＴＮＦα相關的疾病之方法
TW107130340A TWI887196B (zh) 2017-08-30 2018-08-30 用於治療ＴＮＦα相關的疾病之方法
PH12020550066A PH12020550066A1 (en) 2017-08-30 2020-02-27 METHOD FOR TREATING TNFa-RELATED DISEASE
CONC2020/0002117A CO2020002117A2 (es) 2017-08-30 2020-02-27 Métodos para el tratamiento de enfermedades relacionadas con tnfα
CL2020000479A CL2020000479A1 (es) 2017-08-30 2020-02-27 Métodos para el tratamiento de enfermedades relacionadas con tnfa.
ECSENADI202014569A ECSP20014569A (es) 2017-08-30 2020-02-27 Métodos para el tratamiento de enfermedades relacionadas con tnf - alfa
DO2020000049A DOP2020000049A (es) 2017-08-30 2020-02-28 MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
IL272977A IL272977A (en) 2017-08-30 2020-02-28 A method for treating a disease related to TNFα
ZA2020/01927A ZA202001927B (en) 2017-08-30 2020-03-24 Method for treating tnf alpha-related diseases
JP2023196788A JP2024023347A (ja) 2017-08-30 2023-11-20 ＴＮＦα関連疾患の治療方法
US18/774,066 US20250002573A1 (en) 2017-08-30 2024-07-16 Methods for Treating TNFa-Related Diseases
AU2024216469A AU2024216469A1 (en) 2017-08-30 2024-08-30 Method for treating TNF alpha-related disease
KR1020240131000A KR20240148776A (ko) 2017-08-30 2024-09-26 TNFα 관련 질환을 치료하는 방법
ARP250100301A AR135171A2 (es) 2017-08-30 2025-02-04 MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20170110426 2017-08-30
KR1020170110426 2017-08-30
KR1020170144521 2017-11-01
KR20170144521 2017-11-01

Publications (1)

Publication Number Publication Date
KR20190024572A true KR20190024572A (ko) 2019-03-08

Family

ID=65801706

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020180017449A Pending KR20190024572A (ko) 2017-08-30 2018-02-13 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
KR1020180102233A Active KR102921525B1 (ko) 2017-08-30 2018-08-29 TNFα 관련 질환을 치료하는 방법
KR1020240131000A Ceased KR20240148776A (ko) 2017-08-30 2024-09-26 TNFα 관련 질환을 치료하는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020180102233A Active KR102921525B1 (ko) 2017-08-30 2018-08-29 TNFα 관련 질환을 치료하는 방법
KR1020240131000A Ceased KR20240148776A (ko) 2017-08-30 2024-09-26 TNFα 관련 질환을 치료하는 방법

Country Status (27)

Country Link
US (2) US20210371510A1 (cg-RX-API-DMAC7.html)
EP (1) EP3677596A4 (cg-RX-API-DMAC7.html)
JP (2) JP7838891B2 (cg-RX-API-DMAC7.html)
KR (3) KR20190024572A (cg-RX-API-DMAC7.html)
CN (1) CN111094342A (cg-RX-API-DMAC7.html)
AR (1) AR135171A2 (cg-RX-API-DMAC7.html)
AU (2) AU2018326037B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020003951A2 (cg-RX-API-DMAC7.html)
CL (1) CL2020000479A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020002117A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200095A (cg-RX-API-DMAC7.html)
CU (1) CU20200015A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2020000049A (cg-RX-API-DMAC7.html)
EA (1) EA202090544A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20014569A (cg-RX-API-DMAC7.html)
GE (2) GEP20237521B (cg-RX-API-DMAC7.html)
IL (1) IL272977A (cg-RX-API-DMAC7.html)
JO (1) JOP20200046A1 (cg-RX-API-DMAC7.html)
MA (1) MA50046A (cg-RX-API-DMAC7.html)
MX (1) MX2020002278A (cg-RX-API-DMAC7.html)
PE (1) PE20200889A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020550066A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202001739YA (cg-RX-API-DMAC7.html)
TW (1) TWI887196B (cg-RX-API-DMAC7.html)
UA (1) UA130480C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019045452A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202001927B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230045394A1 (en) * 2021-08-06 2023-02-09 AndorHealth, LLC Virtual care systems and methods

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR118191A1 (es) * 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
KR20260087771A (ko) * 2024-12-04 2026-06-12 (주)셀트리온 TNFα 관련 질환을 치료하는 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861335A (en) 1985-07-26 1989-08-29 Duoject Medical Systems Inc. Syringe
US5085642A (en) 1989-07-17 1992-02-04 Survival Technology, Inc. Conveniently carried frequent use autoinjector
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DE69319753T2 (de) 1992-11-19 1999-04-15 Tebro S.A., Luxembourg Automatische injektionsvorrichtung für vorgefüllte spritzen
DE4438360C2 (de) 1994-10-27 1999-05-20 Schott Glas Vorfüllbare partikelarme, sterile Einmalspritze für die Injektion von Präparaten und Verfahren zu ihrer Herstellung
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040131614A1 (en) * 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
TWI439284B (zh) * 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
TWI603739B (zh) * 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
WO2013087914A1 (en) * 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
WO2014114651A1 (en) * 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
EP3078675A1 (en) * 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
KR20170081814A (ko) 2016-01-05 2017-07-13 이경록 헤어 브러시
EP3411401A1 (en) * 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
UA122610C2 (uk) * 2016-06-30 2020-12-10 Селлтріон Інк. Стабільний рідкий фармацевтичний склад

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230045394A1 (en) * 2021-08-06 2023-02-09 AndorHealth, LLC Virtual care systems and methods
US12525346B2 (en) * 2021-08-06 2026-01-13 AndorHealth, LLC Virtual care systems and methods

Also Published As

Publication number Publication date
KR102921525B1 (ko) 2026-02-03
JOP20200046A1 (ar) 2020-02-27
JP2024023347A (ja) 2024-02-21
KR20240148776A (ko) 2024-10-11
TWI887196B (zh) 2025-06-21
EP3677596A4 (en) 2021-07-28
IL272977A (en) 2020-04-30
BR112020003951A2 (pt) 2020-09-08
DOP2020000049A (es) 2020-03-15
ECSP20014569A (es) 2020-07-31
JP2020532520A (ja) 2020-11-12
EP3677596A1 (en) 2020-07-08
CO2020002117A2 (es) 2020-04-01
AU2024216469A1 (en) 2024-09-19
MA50046A (fr) 2020-07-08
WO2019045452A1 (ko) 2019-03-07
SG11202001739YA (en) 2020-03-30
TW202521157A (zh) 2025-06-01
CA3074168A1 (en) 2019-03-07
AU2018326037A1 (en) 2020-01-30
PH12020550066A1 (en) 2021-02-15
AR135171A2 (es) 2026-07-08
NZ760588A (en) 2025-05-30
CU20200015A7 (es) 2020-12-17
GEP20237521B (en) 2023-07-25
AU2018326037B2 (en) 2024-06-27
JP7838891B2 (ja) 2026-04-01
PE20200889A1 (es) 2020-09-03
CN111094342A (zh) 2020-05-01
US20210371510A1 (en) 2021-12-02
TW201919697A (zh) 2019-06-01
MX2020002278A (es) 2020-07-13
KR20190024809A (ko) 2019-03-08
UA130480C2 (uk) 2026-03-04
ZA202001927B (en) 2021-08-25
EA202090544A1 (ru) 2020-06-05
CR20200095A (es) 2020-05-10
GEAP202315302A (en) 2023-04-10
US20250002573A1 (en) 2025-01-02
CL2020000479A1 (es) 2020-10-02

Similar Documents

Publication Publication Date Title
JP7405324B2 (ja) 安定な液体医薬製剤
US20250002573A1 (en) Methods for Treating TNFa-Related Diseases
RU2714919C2 (ru) Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
JP7577674B2 (ja) ＴＮＦα関連疾患の処置方法
CA3239667A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp
US20230115267A1 (en) Pharmaceutical liquid composition having increased stability
US20200157208A1 (en) Combination of an antibody that binds to the p19 subunit of human il-23 and a hyaluronidase enzyme
CA2486147A1 (en) Treatment of crohn&#39;s disease or psoriasis using anti-inteferon gamma antibodies
US20240409631A1 (en) Aqueous formulations of an anti-cd22 antibody and uses thereof
JP2025526402A (ja) 潰瘍性大腸炎及びクローン病治療のための抗ｔｌ１ａ抗体
US20080260730A1 (en) Treatment of Crohn&#39;s disease or psoriasis using anti-interferon gamma antibodies
US20210347878A1 (en) Pharmaceutical composition comprising antibody, device comprising same, and use thereof
KR20250031013A (ko) TNFα 관련 질환을 치료하는 방법
HK40023950A (en) METHOD FOR TREATING TNFα-RELATED DISEASE
EA042970B1 (ru) СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, СВЯЗАННОГО С TNF-α
HK40003220A (en) Stable liquid pharmaceutical preparation

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1204 Withdrawal of earlier application forming a basis of a priority claim

St.27 status event code: N-1-6-B10-B12-nap-PC1204

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000